Plus Therapeutics, Inc.

PSTVNASDAQHealthcare● Active

$5.53

+$0.12(+2.22%)

Market Cap$13380410

P/E Ratio—

52W High$23.5

52W Low$2.9

Avg Volume309K

Open$5.29

Beta1.37

Free Cash Flow Financials Revenue

Plus Therapeutics, Inc. (PSTV) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PSTV · free cash flow · updated Jun 9, 2026

Core FCF metrics

PSTV · FCF · TTM · margin & CAGR

Free cash flow was −$20.8M for FY2025 (fiscal year ending 2025-12-31), down 94.8% year-over-year The FCF margin was -399.8%.

FY2025 Free Cash Flow−$20.8M▼ -94.8% YoY

Trailing 12M (TTM)−$21.7Mtrailing 4 quarters sum

FCF Margin-399.8%−$20.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PSTV · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$20.8M(0M)−$20.8M▼ 94.8%-399.8%

FY2024−$10.6M(0M)−$10.7M▲ +17.8%-183.7%

FY2023−$12.9M(0M)−$13.0M▲ +5.2%-264.8%

FY2022−$13.0M(1M)−$13.7M▼ 31.7%—

FY2021−$10.3M(0M)−$10.4M▼ 16.8%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PSTV · P/FCF · FCF yield · FCF per share

Plus Therapeutics, Inc. (PSTV) reported negative free cash flow of −$0.02B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PSTV · cash flow statement · operating / investing / financing

For FY2025, Plus Therapeutics, Inc. generated −$20.8M in operating cash flow and spent 0M in capital expenditures, yielding −$20.8M in free cash flow.

Operating Activities

−$20.8M

Cash from core business operations

2025-12-31

Investing Activities

−$0.9M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$30.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$20.8M) − |CapEx| (0M) = FCF (−$20.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PSTV vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Plus Therapeutics, Inc.YOU

PSTV

−$20.8M-94.8%-399.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Plus Therapeutics, Inc. (PSTV) reported free cash flow of −$20.8M for FY2025 (fiscal year ending 2025-12-31), down 94.8% year-over-year. The FCF margin was -399.8%.

Plus Therapeutics, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PSTV free cash flow · 8 questions

Plus Therapeutics, Inc. free cash flow was −$20.8M for FY2025, down 94.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$21.7M.

PSTV free cash flowPSTV FCFPSTV FCF 2025PSTV free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Plus Therapeutics, Inc. · Plus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026